Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Liabilities and Shareholders Equity: 2009-2024

Historic Liabilities and Shareholders Equity for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $75.6 million.

  • Cumberland Pharmaceuticals' Liabilities and Shareholders Equity fell 14.14% to $65.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $279.3 million, marking a year-over-year decrease of 12.31%. This contributed to the annual value of $75.6 million for FY2024, which is 7.57% down from last year.
  • As of FY2024, Cumberland Pharmaceuticals' Liabilities and Shareholders Equity stood at $75.6 million, which was down 7.57% from $81.8 million recorded in FY2023.
  • In the past 5 years, Cumberland Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $96.5 million in FY2020 and a low of $75.6 million during FY2024.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Liabilities and Shareholders Equity value was $81.8 million (recorded in 2023), while the average stood at $83.4 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first dropped by 12.44% in 2021, then increased by 10.02% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $96.5 million in 2020, then declined by 12.44% to $84.5 million in 2021, then climbed by 10.02% to $92.9 million in 2022, then declined by 12.00% to $81.8 million in 2023, then declined by 7.57% to $75.6 million in 2024.